Ripretinib

Status:

Do Not Prescribe (DNP)

Decision Date:

June 2023

Comments

DNP: NICE TA881 - Ripretinib for treating advanced gastrointestinal stromal tumour after 3 or more treatments. 

NHS England commissioned - to be used in line with NHSE commissioning intentions. 

Black Drug Classifications

• 6: Have NICE guidance that recommends they should not be used

search again